Medicore, Inc. Reports Second Quarter 2000 Results.

Business Editors

HIALEAH, Fla.--(BUSINESS WIRE)--Aug. 16, 2000

Medicore, Inc. (Nasdaq:MDKI) announced second quarter 2000 revenues of $14,762,000 and a net loss of $316,000 or $.06 per share compared to revenues of $12,527,000 and a net loss of $126,000 or $.02 per share for the second quarter of 1999.

Revenues for the first half of 2000 were $29,854,000 with a net loss of $686,000 or $.12 per share compared to revenues of $23,919,000 with a net loss of $413,000 or $.07 per share for the first half of 1999.

Thomas K. Langbein, Chief Executive Officer and President commented, "Our majority owned public subsidiary, Techdyne, Inc., has shown continued strength in domestic sales, as well as an improvement in sales and reduced losses for its European facility, which causes us to remain optimistic about Techdyne's prospects for the second half of 2000. Techdyne's second quarter results were adversely affected by a worldwide shortage of critical electronic components which delayed shipments and forced Techdyne to purchase these components on the spot market. Techdyne, as are recent forecasters, is hopeful this component shortage will lessen by the fourth quarter. Our other majority owned public subsidiary, Dialysis Corporation of America ("DCA"), reflected increased revenues over the first quarter as it continues to expand the patient base at its centers, which is the key to their achieving profitability. DCA is in the process of constructing a new center in Georgia and is planning the development of a center in Ohio and is continuing its efforts to expand.

Mr. Langbein further remarked, "We maintain our enthusiasm about the association of our new technology division with Linux Global Partners which we feel provides great potential to our company through its Linux software investments. Linux continues to receive positive reviews enhancing its prospects as an alternative to current major computer operating systems.

Medicore manufactures and distributes medical products, invests in and incubates technology companies, and through Techdyne, is an international contract manufacturer of precision electro-mechanical and electronic components for the data processing, telecommunications, instrumentation and food preparation equipment industries through its four U.S. and European production facilities. Medicore is also engaged in the operation of kidney dialysis centers through DCA, which has six centers in Pennsylvania and New Jersey, including its recently opened center in Vineland, New Jersey, with planned expansion into other states.

This release contains forward-looking statements that are subject to risks and uncertainties, including but not limited to, certain delays beyond the Company's control with respect to future business events, general economic conditions, demand for customers' products and services, regulation of dialysis operations, government rate determination for Medicare reimbursement, the highly competitive environment in the operations and acquisition of dialysis centers and manufacture of electro-mechanical components, reliance upon certain major customers in its contract manufacturing segment, the availability of critical electronic components, and other risks detailed from time to time in the Company's fillings with the Securities and Exchange Commission.

              CONSOLIDATED CONDENSED STATEMENTS OF INCOME

                    MEDICORE, INC. AND SUBSIDIARIES
                              (UNAUDITED)


                     Three Months Ended         Six Months Ended
                          June 30,                  June 30,
REVENUES            2000          1999         2000          1999
                    ----          ----         ----          ----
 Sales          $14,606,437   $12,175,190   $29,336,235   $23,434,286
 Realized gain
  on sale of
  marketable
  securities             --       228,078            --       228,078
 Gain on
  subsidiary
  warrants
  exercise            4,970            --       251,330            --
 Other income       150,438       124,184       265,975       256,491
               -------------- -------------- ------------- -----------
                 14,761,845    12,527,452    29,853,540    23,918,855

COST AND EXPENSES

 Cost of goods
  sold           12,380,462    10,423,042    25,294,822    20,243,663
 Selling,
  general and
  administrative
  expenses        2,422,692     2,174,797     4,801,665     4,042,690
 Interest expense   219,123       150,832       425,585       289,854
                -------------  ------------- ------------- -----------
                 15,022,277    12,748,671    30,522,072    24,576,207
                -----------   -----------   -----------    -----------
LOSS BEFORE
 INCOME TAXES
 AND MINORITY
 INTEREST          (260,432)     (221,219)     (668,532)     (657,352)

Income tax
 provision
 (benefit)           91,029        (5,480)      181,646       (50,567)
                 ------------  -------------  ------------ -----------

LOSS BEFORE
 MINORITY INTEREST (351,461)     (215,739)     (850,178)     (606,785)

Minority interest
 in loss of
 consolidated
 subsidiaries       (35,546)      (89,357)     (164,654)     (193,866)
                 -------------  ------------  ------------ -----------

   NET LOSS      $ (315,915)  $  (126,382)   $ (685,524)   $ (412,919)
                 ===========  ============   ===========   ===========

Loss per share:
   Basic              $(.06)        $(.02)        $(.12)        $(.07)
                      ======        ======        ======        ======
   Diluted            $(.06)        $(.02)        $(.12)        $(.07)
                      ======        ======        ======        ======